Background: Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates. Objectives and Methods: We sought to determine the impact of postprocedure MSA on long-term stent patency following abciximab-coated stent (n=69) compared to bare metal stent (BMS) implantation (n=69). All patients underwent IVUS follow-up at 6 months. Results: At follow-up, the restenosis rate and late loss were 12% and 0.30짹0.24 mm in abciximab-coated stent group and 29% and 0.68짹0.36 mm in BMS group (p=0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9짹1.6 mm2 vs. 4.5짹1.7 mm2, p=0.001 and 1.9짹1.5 mm2 vs. 3.3짹1.9 mm2, p < 0.001, respectively). In-stent restenosis was observed in 10%, 1%, and 0% in abciximab-coated stent group and 22%, 6%, and 1% in BMS group in lesions with a MSA <6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Target lesion revascularization occurred in 9%, 0%, and 0% in abciximab-coated stent group and 19%, 4%, and 1% in BMS group in lesions with a MSA <6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Conclusion: Abciximab-coated stent reduced restenosis effectively and postprocedure MSA > 6 mm2 may be sufficient to qualify as an optimal IVUS results.